EPH Receptor A4 anticorps (C-Term)
Aperçu rapide pour EPH Receptor A4 anticorps (C-Term) (ABIN2469317)
Antigène
Voir toutes EPH Receptor A4 (EPHA4) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- C-Term
-
Specificité
- BLAST analysis of the peptide immunogen showed no homology with other human proteins.
-
Purification
- Immunoaffinity Chromatography
-
Immunogène
- EPHA4 antibody was raised against a peptide located in the C-Terminal domain of EPHA4 (Human).
-
-
-
-
Indications d'application
- EPHA4 antibody can be used in immunohistochemistry starting at 7.3 μg/mL.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- PBS, 0.1 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- As with all antibodies avoid freeze/thaw cycles.
-
Stock
- 4 °C/-80 °C
-
Stockage commentaire
- EPHA4 antibody should be stored long term (months) at -80 °C and short term (days) at 4 °C.
-
-
- EPH Receptor A4 (EPHA4)
-
Autre désignation
- EPHA4
-
Sujet
- Nak1, a NR4 Nerve Growth Factor-Like receptor, has been shown to affect the hypothalamic-pituitary axis, neuronal differentiation, neuroendocrine regulation of adrenocortical function, and T-cell apoptosis. Nak1 also is known as nuclear receptor Tr3 and is similar to mouse Nur77 and rat NGFI-B. It is encoded by one of the immediate early genes (IEG) in response to nerve growth factor and other serum growth factors. Nak1 can bind to DNA as a monomer, homodimer, or heterodimer (with retinoid X receptors). Nak1 has been shown to inhibit vascular lesion formation and could serve as a novel target in the treatment of vascular diseases.
-
ID gène
- 2043
-
UniProt
- P54764
-
Pathways
- Signalisation RTK
Antigène
-